Study guide

10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

ASCP Molecular Biology Technologist MB

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Strategy

1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy

2 Nucleic Acid Chemistry & Molecular Structure

2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation

3 Central Dogma, Genome Organization & Cytogenetics

3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations

4 Biochemical Reagents & Enzymes

4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives

5 Nucleic Acid Isolation & Purification

5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices

6 Nucleic Acid Quantification & Electrophoresis

6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics

7 PCR Principles & Primer Design Optimization

7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting

8 Advanced Amplification Technologies

8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification

9 DNA Sequencing Technologies

9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics

10 Hybridization, Blotting & Cytogenetic Assays

10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

11 Molecular Infectious Disease Diagnostics

11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing

12 Molecular Oncology & Hematopathology

12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

13 Medical Genetics, Pharmacogenomics & Identity Testing

13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism

14 Quality Assurance, Controls & Method Validation

14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency

15 Laboratory Operations, Safety & Clinical Variant Reporting

15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS

10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

Key Takeaways Explain This Topic AI

Microarray platforms immobilize hundreds of thousands to millions of distinct, sequence-defined oligonucleotide or BAC probe features at known spatial coordinates on a solid glass or silicon surface for parallel nucleic acid interrogation.

Array Comparative Genomic Hybridization (aCGH) co-hybridizes differentially labeled patient (Cy5, red) and sex-matched normal reference (Cy3, green) genomic DNA to quantify copy number variations (CNVs), where normalized log2(Cy5/Cy3) ratios distinguish diploid normal (0.0), single-copy duplication (+0.58), and single-copy deletion (-1.0).

Single Nucleotide Polymorphism (SNP) microarrays measure both total hybridization intensity (Log R Ratio, LRR) and allelic fraction (B-Allele Frequency, BAF), uniquely identifying copy-neutral loss of heterozygosity (CN-LOH), uniparental disomy (UPD), and runs of homozygosity (ROH).

Chromosomal microarray (CMA) is recommended as the primary first-tier clinical diagnostic test for individuals with unexplained developmental delay, intellectual disability, autism spectrum disorder, and multiple congenital anomalies.

Microarrays cannot detect balanced chromosomal rearrangements (such as reciprocal translocations, balanced inversions, and Robertsonian translocations), low-level mosaicism (<10%–20%), or single-nucleotide point mutations, requiring complementary karyotyping, FISH, or NGS for comprehensive diagnostic assessment.

Last updated: August 2026

10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

Quick Summary: Microarray technology immobilizes hundreds of thousands to millions of microscopic, sequence-defined nucleic acid probe features onto solid glass or silicon substrates, enabling massively parallel genomic interrogation. Array Comparative Genomic Hybridization (aCGH) employs two-color competitive hybridization (patient DNA labeled with Cy5 vs. reference DNA labeled with Cy3 ) to detect submicroscopic copy number variants (CNVs) across the entire genome based on normalized log ⁡ 2 ( Cy5/Cy3 ) \log_2(\text{Cy5/Cy3}) lo g 2 ​ ( Cy5/Cy3 ) ratios . Single Nucleotide Polymorphism (SNP) microarrays provide dual orthogonal metrics: Log R Ratio (LRR) for total copy number and B-Allele Frequency (BAF) for allelic distribution. This dual capability allows SNP arrays to uniquely identify copy-neutral loss of heterozygosity (CN-LOH) , uniparental disomy (UPD) , and consanguinity , which are completely invisible to conventional aCGH. Chromosomal microarray (CMA) serves as the primary first-tier clinical diagnostic standard for developmental delay and congenital anomalies.

1. Microarray Architecture & Physical Substrates

A microarray is a miniaturized, ordered arrangement of immobilized single-stranded DNA oligonucleotides or cloned genomic fragments attached to a planar solid support (typically a silanized microscope glass slide or silica bead chip). +---------------------------------------------------------------------------------------------------------+

  • | MICROARRAY PLATFORM ARCHITECTURES |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | Microarray Platform | Substrate & Probe Synthesis | Analytical Capabilities & Resolution |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Oligonucleotide** | High-density 60-mer synthetic | High resolution (10–25 kb); sequence-specific;|
  • | **aCGH (Agilent)** | oligonucleotides synthesized *in* | covers coding exons and intergenic backbones; |
  • | | *situ* via inkjet phosphoramidite | detects microdeletions and microduplications. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **BAC / PAC** | Bacterial Artificial Chromosomes | Historical legacy platform; low resolution |
  • | **Arrays (Legacy)** | (100–200 kb genomic inserts) | (1–5 Mb); replaced by high-density synthetic |
  • | | spotted mechanically onto glass | oligonucleotide and SNP arrays. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Illumina Infinium**| 50-mer probes attached to 3 µm | Dual CNV + SNP genotyping (500k to >2M SNPs); |
  • | **BeadArray** | silica beads residing in etched | single-base extension incorporates labeled |
  • | | microwells on a silicon chip | dideoxynucleotide (ddNTP) hapten. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Affymetrix / Cyto**| High-density 25-mer oligos | Dual CNV + SNP interrogation (>2.6M markers); |
  • | **Scan (Thermo)** | photolithographically synthesized | whole-genome coverage of structural gains, |
  • | | directly on a quartz glass wafer | losses, LOH, and mosaicism down to 5–10%. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • 2. Array Comparative Genomic Hybridization (aCGH) Mechanics

In traditional metaphase CGH (developed by Kallioniemi in 1992), labeled patient and reference DNA were hybridized to normal metaphase chromosome spreads on a slide, limiting resolution to 5 – 10 Mb 5–10\text{ Mb} 5–10 Mb . Array CGH replaced metaphase chromosomes with thousands of sequence-defined genomic probes, improving diagnostic resolution down to 10 – 50 kb 10–50\text{ kb} 10–50 kb . THE aCGH TWO-COLOR HYBRIDIZATION WORKFLOW

  • [ Patient Genomic DNA ] (500 ng) [ Reference Genomic DNA ] (500 ng)
  • | |
  • v [Random Primed Labeling (Klenow)] v [Random Primed Labeling (Klenow)]
  • [ Labeled with Cy5 (Red, 650 nm) ] [ Labeled with Cy3 (Green, 550 nm) ]
  • \ /
  • \ /
  • v v
  • [ Combine Equal Masses + Add Human Cot-1 DNA to Block Repetitive Sequences ]
  • |
  • v
  • [ Co-Hybridize onto Oligonucleotide Glass Array Slide (40–48 hrs at 65°C) ]
  • |
  • v
  • [ Dual-Laser Microarray Scanner (635 nm Laser for Cy5 / 532 nm Laser for Cy3) ]
  • |
  • v
  • [ Calculate Normalized Fluorescence Ratio: log2(Cy5 Intensity / Cy3 Intensity) ]
  • Mathematical Derivation of log ⁡ 2 \log_2 lo g 2 ​ Ratios

The relative copy number at any specific genomic locus is calculated from the normalized fluorescence emission of the patient channel (Cy5, Red) divided by the reference channel (Cy3, Green): Normalized Ratio = Fluorescence Intensity of Cy5 (Patient) Fluorescence Intensity of Cy3 (Reference) \text{Normalized Ratio} = \frac{\text{Fluorescence Intensity of Cy5 (Patient)}}{\text{Fluorescence Intensity of Cy3 (Reference)}} Normalized Ratio = Fluorescence Intensity of Cy3 (Reference) Fluorescence Intensity of Cy5 (Patient) ​ Theoretical log ⁡ 2 Ratio = log ⁡ 2 ( Patient Copy Number Reference Copy Number ) \text{Theoretical } \log_2\text{ Ratio} = \log_2\left(\frac{\text{Patient Copy Number}}{\text{Reference Copy Number}}\right) Theoretical lo g 2 ​ Ratio = lo g 2 ​ ( Reference Copy Number Patient Copy Number ​ ) +---------------------------------------------------------------------------------------------------------+

  • | THEORETICAL aCGH LOG2 RATIO INTERPRETATION |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | Genomic Copy State | Ratio (Pt : Ref) | Theoretical Log2 Value| Mathematical Derivation |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Diploid Normal** | 2 : 2 (1.0) | **0.00** | $\log_2(2/2) = \log_2(1.0) = 0$ |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Single Deletion** | 1 : 2 (0.5) | **-1.00** | $\log_2(1/2) = \log_2(0.5) = -1.00$ |
  • | (Heterozygous Loss) | | (Observed: -0.6 to -1)| (Shifted toward 0 by normal stromal) |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Homozygous Del** | 0 : 2 (0.0) | **$-\infty$** | $\log_2(0/2) = -\infty$ |
  • | (Complete Loss) | | (Observed: < -2.0) | (Residual background fluorescence) |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Single Duplication| 3 : 2 (1.5) | **+0.585** | $\log_2(3/2) = \log_2(1.5) = +0.585$ |
  • | (Heterozygous Gain) | | (Observed: +0.3 to +0.5| |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Double Duplication| 4 : 2 (2.0) | **+1.00** | $\log_2(4/2) = \log_2(2.0) = +1.00$ |
  • | (Tetrasomy / Gain)**| | (Observed: +0.8 to +1)| |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **High Amplification| > 5 : 2 (> 2.5) | **> +1.32** | $\log_2(>5/2) = \log_2(>2.5) > +1.32$ |
  • | (e.g., Oncogene amp)| | | (e.g., MYCN, ERBB2 amplification) |

+---------------------+-------------------+-----------------------+---------------------------------------+ aCGH CHROMOSOME PLOT DISPLAY

  • log2 Ratio
  • +1.0 | [ DUPLICATION (+0.58) ]
  • | * * * * * * * * *
  • 0.0 | - - * - * - * - * - * - - - - - - - - - - - - - - - - - - * - * - * - - Diploid Baseline
  • | * * * * * *
  • 1.0 | [ DELETION (-1.0) ]
  • +--------------------------------------------------------------------> Chromosome Position
  • pter qter
  • 3. SNP Microarrays: Dual LRR & BAF Deconvolution

While aCGH measures total copy number via two-color competitive hybridization, Single Nucleotide Polymorphism (SNP) arrays measure two independent, orthogonal parameters at millions of individual single-nucleotide coordinates. +---------------------------------------------------------------------------------------------------------+

  • | ORTHOGONAL SNP ARRAY METRICS |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | Metric Name | Mathematical Definition | Diagnostic Information Provided |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Log R Ratio** | $\text{LRR} = \log_2(R_{\text{obs}}| **Copy Number / Total Dosage:** |
  • | **(LRR)** | / R_{\text{exp}})$ where $R$ is | Reflects total hybridization signal intensity |
  • | | total probe fluorescence $(A + B)$| ($\text{LRR} \approx 0$ normal; $>0$ gain; $<0$ loss) |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **B-Allele** | $\text{BAF} = \frac{I_B}{I_A + I_B}$| **Allelic Imbalance & Genotype:** |
  • | **Frequency (BAF)** | Normalized proportion of signal | Reflects the ratio of B-allele to total A+B; |
  • | | contributed by the 'B' allele | reveals discrete genotype tracks ($0, 0.5, 1$) |
  • +---------------------+-----------------------------------+-----------------------------------------------+

Deconvoluting Genotypes on LRR and BAF Plots +---------------------------------------------------------------------------------------------------------+

  • | SNP ARRAY GENOTYPIC PROFILES ACROSS LRR & BAF |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | Biological State | Log R Ratio (LRR) | BAF Track Pattern | Observed Genotypes |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Diploid Normal** | $\text{LRR} \approx 0$| **3 Tracks:** | $AA = 0.0$ |
  • | (Disomy, 2 copies) | | $0.0$, $0.5$, $1.0$ | $AB = 0.5$ |
  • | | | | $BB = 1.0$ |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Hemizygous** | $\text{LRR} < 0$ | **2 Tracks:** | $A = 0.0$ |
  • | **Deletion (Loss)** | ($\approx -0.55$) | $0.0$, $1.0$ | $B = 1.0$ |
  • | (1 copy remaining) | | (Loss of $0.5$ track) | (Heterozygous AB state destroyed) |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Homozygous** | $\text{LRR} \ll 0$| **No discrete tracks**| No DNA remaining |
  • | **Deletion (Null)** | ($<-2.0$) | (Random noise) | (Complete signal loss) |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Duplication** | $\text{LRR} > 0$ | **4 Tracks:** | $AAA = 0.0$ |
  • | **(Trisomy, Gain)** | ($\approx +0.35$) | $0.0, 0.33, 0.67, 1.0$| $AAB = 0.33$ |
  • | (3 copies) | | (Split middle track) | $ABB = 0.67$, $BBB = 1.0$ |
  • +---------------------+-------------------+-----------------------+---------------------------------------+
  • | **Copy-Neutral LOH**| **LRR = 0.0** | **2 Tracks:** | $AA = 0.0$ |
  • | **(CN-LOH / aUPD)** | **(Normal Copy!)**| $0.0$, $1.0$ | $BB = 1.0$ |
  • | (2 identical copies)| | (Absence of $AB=0.5$) | (Megabase loss of heterozygosity!) |

+---------------------+-------------------+-----------------------+---------------------------------------+ SNP ARRAY COPY-NEUTRAL LOH (CN-LOH) SIGNATURE

  • Log R Ratio (LRR)
  • +1.0 |

0.0 | - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Normal Baseline!

  • 1.0 |
  • +--------------------------------------------------------------------->
  • B-Allele Frequency (BAF)
  • 1.0 | * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (BB Genotype)
  • |
  • 0.5 | * * * * * * * * * * [ NO AB TRACK! ] * * * * * * * (Heterozygous AB)
  • |
  • 0.0 | * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * (AA Genotype)
  • +--------------------+-----------------------------------+------------->
  • Normal Diploid Flank REGION OF CN-LOH / aUPD Normal Flank
  • Why aCGH Cannot Detect Copy-Neutral LOH (CN-LOH)

Copy-Neutral Loss of Heterozygosity (CN-LOH) —also known as acquired uniparental disomy (aUPD) —occurs when a cell loses one parental allele and duplicates the remaining homologous allele via mitotic recombination or nondisjunction rescue.

Total copy number remains exactly 2 .

In aCGH, because total patient DNA hybridizes at a 2 : 2 2:2 2 : 2 ratio with normal diploid reference DNA, the calculated log ⁡ 2 ( Ratio ) \log_2(\text{Ratio}) lo g 2 ​ ( Ratio ) is exactly 0.00 0.00 0.00 . aCGH is completely blind to CN-LOH.

In SNP arrays, while the LRR is 0.0 0.0 0.0 , the BAF track instantly reveals the complete loss of all heterozygous A B AB A B SNPs ( 0.5 0.5 0.5 frequency) over contiguous megabase segments, exposing the abnormal isodisomy.

Clinical Significance: Identifies imprinting disorders (e.g., Uniparental Disomy in Prader-Willi / Angelman syndromes on chromosome 15, Beckwith-Wiedemann syndrome on 11p15.5) and oncogenic homozygosity of tumor suppressor mutations (e.g., TP53 , FLT3 , JAK2 V617F in AML/MDS).

4. Clinical Indications & Professional ACMG Guidelines

The American College of Medical Genetics and Genomics ( ACMG ) and the American Academy of Pediatrics ( AAP ) endorse Chromosomal Microarray (CMA) as the first-tier diagnostic test for:

  • Unexplained Developmental Delay (DD) and Intellectual Disability (ID)
  • Autism Spectrum Disorders (ASD)

Multiple Congenital Anomalies (MCA) not fitting a well-defined monogenic syndrome +---------------------------------------------------------------------------------------------------------+

  • | MICROARRAY VS. G-BAND KARYOTYPING |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | Parameter | G-Banded Karyotyping | Chromosomal Microarray (CMA) |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Resolution** | **5 to 10 Mb** (low resolution) | **10 to 50 kb** (>100-fold higher resolution!)|
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Cell Culture** | Mandatory; requires living cells | None; uses extracted DNA from uncultured blood|
  • | | arrested in metaphase | saliva, skin, or fresh/frozen tissue |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Diagnostic Yield**| 3% to 5% in DD/ID/ASD cohorts | **15% to 20%** in DD/ID/ASD cohorts |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Submicroscopic** | Invisible (below optical limit) | Easily detects DiGeorge (22q11.2), Williams |
  • | **Microdeletions** | | (7q11.23), Prader-Willi/Angelman (15q11-q13) |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Balanced Trans-** | **Detected easily** (visualizes | **Completely blind**; no copy number change! |
  • | **locations** | chromosome structural movements) | |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • 5. Inherent Limitations of Microarray Platforms

Understanding what microarrays cannot detect is a primary focus of clinical competency and the ASCP MB examination. +---------------------------------------------------------------------------------------------------------+

  • | WHAT MICROARRAYS CANNOT DETECT |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | Structural Variant Type | Biochemical / Biophysical Reason for Diagnostic Invisibility |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Balanced Reciprocal** | Involves mutual exchange of chromosomal segments without any gain or loss |
  • | **Translocations** | of genomic material ($\log_2\text{ Ratio} = 0.00$; $\text{LRR} = 0.00$). |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Balanced Inversions** | DNA segment is inverted 180° in orientation; total copy number is normal. |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Robertsonian Trans-** | Fusion of acrocentric p-arms (containing non-essential rDNA); balanced. |
  • | **locations (Balanced)** | |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Gene Relocations / Tandem**| Arrays identify gain of a segment but cannot determine its spatial |
  • | **vs. Insertional Position**| location (e.g., tandem duplication on chr 1 vs inserted into chr 12). |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Low-Level Mosaicism** | Minor clonal sub-populations (<10% to 20% mutant cells) are submerged in |
  • | | background diploid signal noise. |
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Single-Nucleotide SNVs** | Point mutations (e.g., *CFTR* F508del, *BRAF* V600E) and tiny indels |
  • | **and Small Indels (<10 kb)**| are not detected unless directly interrogated by specific single-base SNPs|
  • +-----------------------------+---------------------------------------------------------------------------+
  • | **Trinucleotide Expansions**| Repetitive expansions (*FMR1*, *HTT*) do not alter copy number probes. |
  • +-----------------------------+---------------------------------------------------------------------------+
  • 6. Microarray Quality Control Metrics & Clinical Troubleshooting

To guarantee diagnostic validity under CAP/CLIA regulations, laboratories analyze mathematical quality metrics before releasing clinical array data. +---------------------------------------------------------------------------------------------------------+

  • | ARRAY QUALITY CONTROL BENCHMARKS |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | QC Metric | Clinical Diagnostic Benchmark | Significance & Failure Root Cause |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Derivative Log** | **DLRSpread < 0.20 to 0.30** | Measures probe-to-probe noise across adjacent |
  • | **Ratio Spread** | (Agilent aCGH platforms) | chromosomal features. Elevated by degraded |
  • | **(DLRSpread)** | | DNA, poor labeling, or uneven hybridization. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **SNP Call Rate** | **> 98.5% to 99.0%** | Percentage of SNP features assigned a high- |
  • | | (Illumina / Affymetrix arrays) | confidence discrete genotype. Reduced by poor |
  • | | | DNA quality, low input mass, or inhibitors. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Specific** | **> 8.0 to 10.0 pmol dye / µg** | Measures fluorophore incorporation efficiency |
  • | **Activity** | for Cy5 and Cy3 | during random priming with Klenow fragment. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • | **Signal-to-Noise** | **SNR > 10.0** | Ratio of mean feature foreground intensity to |
  • | **Ratio (SNR)** | for all scanning channels | surrounding background noise. |
  • +---------------------+-----------------------------------+-----------------------------------------------+
  • Systematic Array Troubleshooting Guide

Visual / Analytical Anomaly Root Cause Corrective Action

Elevated DLRSpread ( > 0.35 >0.35 > 0.35 ) / High Wave Noise Degraded input genomic DNA; salt/solvent contamination; bubbles during hybridization Verify DNA integrity via Agilent Bioanalyzer / TapeStation (DIN > 7.0 >7.0 > 7.0 required); re-purify DNA with silica columns; roll out bubbles during array chamber assembly.

Wavy Baseline Across Chromosomes (GC Wave) Systematic labeling bias or hybridization artifact correlating with local genomic GC content Apply bioinformatic GC-wave correction algorithms (LOESS / spline smoothing); ensure equal DNA input quantities for Cy5 and Cy3.

Severe Dye Bias / Unbalanced Channels Unequal labeling efficiency between Cy5 and Cy3; Cy5 ozone degradation Measure specific activity spectrophotometrically prior to pooling; protect Cy5 from ambient atmospheric ozone ( < 5 ppb <5\text{ ppb} < 5 ppb ) or use ozone-free enclosures.

Localized Donut / Ring Artifacts on Scan Air bubble trapped under array gasket during 65°C incubation; dust on glass Ensure hybridization rotator oven operates at correct RPM; handle slides in certified cleanroom / HEPA-filtered laminar flow hoods.

Low SNP Call Rate ( < 95 % <95\% < 95% ) Inadequate genomic DNA input mass ( < 200 ng <200\text{ ng} < 200 ng ); incomplete single-base extension enzymology Accurately quantify input DNA using fluorometry (Qubit dsDNA BR); verify reagent expiration dates on enzyme extension master mix.

Loading diagram... aCGH Two-Color Workflow and SNP Array Dual LRR / BAF Metric Interpretation